Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs provides clients worldwide with a diverse range of ATP7B-targeted recombinant antibodies through our advanced platforms. Our dedication to advancing research and discovery is backed up by exceptional value and unrivaled technical support, allowing our clients to achieve their scientific objectives efficiently.
The ATP7B protein, found in the trans-Golgi network of the liver and brain, plays a crucial role in maintaining copper homeostasis by facilitating the excretion of excess copper into bile and plasma. Mutations in the ATP7B gene often lead to Wilson's disease, a genetic disorder characterized by the accumulation of copper in tissues. This accumulation can result in severe neurological or psychiatric symptoms, liver disease, and can be fatal if not treated. Due to the essential function of ATP7B in copper regulation, it presents a promising target for the development of specific therapeutics aimed at treating Wilson’s disease.
Wilson disease protein; WND; PWD; WC1; WD; ATPase copper transporting beta; Copper Pump 2; Copper-Transporting ATPase 2; ATPase, Cu++ Transporting, Beta Polypeptide; Wilson Disease-Associated Protein; ATPase, Cu++ Transporting, Beta Polypeptide (Wilson Disease); ATPase Cu(2+)- Transporting Beta Polypeptide; Copper-Transporting Protein ATP7B; Wilson Disease; EC 7.2.2.8; EC 3.6.3.4; EC 3.6.3.
Cancer-related genes, Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Transporters
Membrane
Cell type enhanced (Late spermatids, Early spermatids, Inhibitory neurons, Excitatory neurons, Hepatocytes, Cone photoreceptor cells)
Not detected in immune cells
Cell line enhanced (BEWO, CACO-2, HEL, RPTEC TERT1)
Monomer. Interacts with COMMD1/MURR1 (PubMed:12968035, PubMed:17919502). Interacts with DCTN4, in a copper-dependent manner (PubMed:16554302). Interacts with ATOX1 (PubMed:18558714, PubMed:17919502). Interacts (via C-terminus) with ZBTB16/PLZF (PubMed:16676348).
Translocase
We are dedicated to advancing research and innovation by providing high-quality anti-ATP7B recombinant antibodies at excellent value, along with comprehensive technical support. Here are some recombinant antibodies that target ATP7B. To get all the details and choose the optimal choice, kindly click on the provided link.
Cat. No. | Product Name | Target Species | Host Species | Applications |
NABG-020 | Recombinant Anti-Human ATP7B VHH Single Domain Antibody | Human | Llama VHH | WB, ELISA, IHC, FS, etc. |
MOB-0857MZ | Mouse Anti-ATP7B Recombinant Antibody (clone CBLS-150) | Human | Mouse IgG1 | WB |
MOR-0300 | Hi-Affi™ Rabbit Anti-ATP7B Recombinant Antibody (clone DS300AB) | Human | Rabbit IgG | WB, ICC, FC |
Our mission is to improve the biopharmaceutical industry by offering high-quality products and excellent customer service. Through our stringent quality management system, we ensure that our offerings not only meet but also exceed industry standards. This commitment to excellence improves drug development efficiency while also providing our clients with unrivaled value and reliability.
Our state-of-the-art mammalian cell expression platform is designed to be serum-free. We provide a full range of services, including gene synthesis and scalable, high-quality anti-ATP7B recombinant antibody production. A combination of our five years of process optimization experience, we efficiently and affordably provide solutions for different quantities of antibodies.
Featured Anti-ATP7B Recombinant Antibody Production Platforms
Fig.1 Milligram-scale anti-ATP7B recombinant antibody production.
Fig.2 Gram-scale anti-ATP7B recombinant antibody production.
Creative Biolabs offers a wide range of premium anti-ATP7B recombinant antibodies in different formats, including full-length, Fab, scFv, and more. With our deep knowledge and vast experience in antibody engineering, we are fully equipped to offer tailored solutions that perfectly align with clients’ unique research requirements.
Fig.3 Full-Length Anti-ATP7B Recombinant Antibody Production and Modalities.
Table 1. ATP7B-targeted drug information.
Company | Highest Phase | Classification | Condition |
Ultragenyx (Originator) | Phase I/II |
Adeno-Associated Viral (AAV) Vectors Gene Therapy |
Wilson's disease |
Pfizer Vivet Therapeutics (Originator) |
Phase I/II |
Adeno-Associated Viral (AAV) Vectors Gene Therapy |
Wilson's disease |
Skyline Therapeutics (Originator) | Preclinical |
Adeno-Associated Viral (AAV) Vectors Gene Therapy |
Wilson's disease |
West China Hospital of Sichuan University (Originator) | Preclinical |
Adeno-Associated Viral (AAV) Vectors Gene Therapy |
Wilson's disease |
Shanghai Jiao Tong University (SJTU) (Originator) | Preclinical |
Adeno-Associated Viral (AAV) Vectors CRISPR/Cas9 System Nucleases Gene Therapy Single Guide RNA (sgRNA) Single-stranded oligoribonucleotide (RNA) |
Genetic Disorders |
Aligen Therapeutics (Originator) Centro Investigacion Medica Aplicada (Originator) Universidad de Navarra (Originator) |
Preclinical |
Adeno-Associated Viral (AAV) Vectors Gene Therapy |
Wilson's disease |
Nanjing First Hospital (Originator) | Preclinical |
Mesenchymal Stem Cells Stem Cell-Based Gene Therapy Stem Cell Therapy |
Wilson's disease |
Children's Hospital of Philadelphia (Originator) | Preclinical | Gene Therapy | Wilson's disease |
Oxford BioMedica (Originator) | Biological Testing |
Gene Therapy Lentiviral Vectors |
Wilson's disease |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
If you have any further questions about our anti-ATP7B recombinant antibody products, please contact us as soon as possible. We are excited about the prospect of identifying potential collaborative partnerships that will benefit both parties and advance your research.